Skip to content

What Are The Rumors About The Relationship Between Vertex Pharmaceuticals And Sarepta Therapeutics ?

December 2, 2012

       On November 28, 2012, the Internet was buzzing about the relationship between Vertex Pharmaceuticals and Sarepta Therapeutics. Per a article titled, “Sarepta Gains From Vertex Info …..”, Sarepta Therapeutics’ stock shares increased by 5% on the day following Vertex Pharmaceuticals’ presentation with “ … in-depth information in regards to Sarepta’s treatment for Duchenne Muscular Dystrophy …”. 

         A article titled, “Sarepta advances following inclusion in Vertex presentation”, suggests that even though other companies’ drugs are mentioned in Vertex Pharmaceuticals’ presentation, the information presented about Sarepta Therapeutics’ Eteplirsen is more detailed than the others. This led to some investors wondering whether or not Vertex Pharmaceuticals may be interested in buying rights to Eteplirsen or a possible takeover by Vertex Pharmaceuticals.  

        The presentation titled, “Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis”, is posted online on the European Medicines Agency (EMA) website. It is presented by Federico Goodsaid, Vice President of Strategic Regulatory Intelligence, at Vertex Pharmaceuticals. Pages 1 – 27 reviews Vertex Pharmaceuticals’ orphan drug Kalydeco (Ivacaftor). Pages 28 – 36, presents case studies of other applications in drug development and regulatory review for Gaucher Disease and Duchenne Muscular Dystrophy (DMD).   

Copyright © 2012-2013, Orphan Druganaut Blog.  All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: